Back to Search Start Over

Endothelin-1 influences mechanical properties and contractility of hiPSC derived cardiomyocytes resulting in diastolic dysfunction.

Authors :
Redwanz C
Pires RH
Biedenweg D
Groß S
Otto O
Könemann S
Source :
Journal of molecular and cellular cardiology [J Mol Cell Cardiol] 2024 Sep; Vol. 194, pp. 105-117. Date of Electronic Publication: 2024 Jul 15.
Publication Year :
2024

Abstract

A better understanding of the underlying pathomechanisms of diastolic dysfunction is crucial for the development of targeted therapeutic options with the aim to increase the patients' quality of life. In order to shed light on the processes involved, suitable models are required. Here, effects of endothelin-1 (ET-1) treatment on cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) were investigated. While it is well established, that ET-1 treatment induces hypertrophy in cardiomyocytes, resulting changes in cell mechanics and contractile behavior with focus on relaxation have not been examined before. Cardiomyocytes were treated with 10 nM of ET-1 for 24 h and 48 h, respectively. Hypertrophy was confirmed by real-time deformability cytometry (RT-DC) which was also used to assess the mechanical properties of cardiomyocytes. For investigation of the contractile behavior, 24 h phase contrast video microscopy was applied. To get a deeper insight into changes on the molecular biological level, gene expression analysis was performed using the NanoString nCounter® cardiovascular disease panel. Besides an increased cell size, ET-1 treated cardiomyocytes are stiffer and show an impaired relaxation. Gene expression patterns in ET-1 treated hiPSC derived cardiomyocytes showed that pathways associated with cardiovascular diseases, cardiac hypertrophy and extracellular matrix were upregulated while those associated with fatty acid metabolism were downregulated. We conclude that alterations in cardiomyocytes after ET-1 treatment go far beyond hypertrophy and represent a useful model for diastolic dysfunction.<br />Competing Interests: Declaration of competing interest Oliver Otto is co-founder of Zellmechanik Dresden commercializing real-time deformability cytometry. All other authors declare that they have no conflict of interest. The authors did not use generative AI or AI-assisted technologies in the development of this manuscript.<br /> (Copyright © 2024. Published by Elsevier Ltd.)

Details

Language :
English
ISSN :
1095-8584
Volume :
194
Database :
MEDLINE
Journal :
Journal of molecular and cellular cardiology
Publication Type :
Academic Journal
Accession number :
39019395
Full Text :
https://doi.org/10.1016/j.yjmcc.2024.07.004